Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition

This article was originally published in The Pink Sheet Daily

Executive Summary

Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.

Advertisement

Related Content

Deals Of The Week: Tire-Kicking Season Continues Full-Swing
Celgene’s Bet On Abraxis Helps Spur Host Of Nanomedicine Start-Ups
Deerfield Management Opts For More Private Investment And A New Public Face
The Future Of Private Biotech Investment: A Q&A With Jonathan Leff
Talon’s Marqibo Faces Commercial Challenges After FDA Approval
Marqibo Clears FDA Despite Advisory Committee Concerns About Confirmatory Trial

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075982

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel